Sharma Mani
Known title: See remarksCIK: 0002122411
Sharma Mani's purchase track record
Sharma Mani has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/8/2026 | AZN | $3K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AZN | ▲ Buy | Grant | 2 | $320 | 10/6/2026 | View on chart |
| AZN | ▲ Buy | Grant | 1 | $163 | 9/8/2026 | View on chart |
| AZN | ▲ Buy | Open Market | 20 | $3K | 8/8/2026 | View on chart |
| AZN | ▲ Buy | Grant | 2 | $327 | 8/6/2026 | View on chart |
| AZN | ▲ Buy | Grant | 2 | $381 | 7/6/2026 | View on chart |
| AZN | ▲ Buy | Grant | 1 | $180 | 6/8/2026 | View on chart |
| AZN | ▼ Sell | Open Market | 11,893 | $2.2M | 5/20/2026 | View on chart |
| AZN | ▲ Buy | Grant | 1 | $186 | 5/6/2026 | View on chart |
| AZN | ▲ Buy | Grant | 1 | $196 | 4/7/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AZN Announces AI Drug Discovery Partnership and Trial Outlook
AstraZeneca disclosed a new partnership with insitro to use artificial intelligence for drug discovery in MASH and cardiomyopathies. The collaboration aims to accelerate early‑stage research and could expand the company's pipeline. Around the same time, RBC reaffirmed an outperform rating ahead of the AVANZAR lung‑cancer trial, while the stock outperformed the broader market in recent trading. These developments add focus to both innovative research and upcoming clinical data.
AZN Announces AI Drug Discovery Partnership and Trial Outlook. AstraZeneca disclosed a new partnership with insitro to use artificial intelligence for drug discovery in MASH and cardiomyopathies. The collaboration aims to accelerate early‑stage research and could expand the company's pipeline. Around the same time, RBC reaffirmed an outperform rating ahead of the AVANZAR lung‑cancer trial, while the stock outperformed the broader market in recent trading. These developments add focus to both innovative research and upcoming clinical data.